

with all types of containments used in this country demonstrates that essentially all containment leakage can be detected by local leakage rate tests (Type B and C). According to results given in NUREG-1493, out of 180 ILRT reports covering 110 individual reactors and approximately 770 years of operating history, only 5 ILRT failures were found which local leakage rate testing could not detect. This is 3% of all failures. This study agrees well with previous NRC staff studies which show that Type B and C testing can detect a very large percentage of containment leaks. The Prairie Island Nuclear Generating Plant, Unit No. 2, experience has also been consistent with these results.

The Nuclear Management and Resources Council (NUMARC), now the Nuclear Energy Institute (NEI), collected and provided the NRC staff with summaries of data to assist in the Appendix J rulemaking effort. NUMARC collected results of 144 ILRTs from 33 units; 23 ILRTs exceeded $1L_a$. Of these, only nine were not type B or C leakage penalties. The NEI data also added another perspective. The NEI data show that in about one-third of the cases exceeding allowable leakage, the as-found leakage was less than $2L_a$; in one case the leakage was found to be approximately $2L_a$; in one case the as-found leakage was less than $3L_a$; one case approached $10L_a$; and in one case the leakage was found to be approximately $21L_a$. For about half of the failed ILRTs the as-found leakage was not quantified. These data show that, for those ILRTs for which the leakage was quantified, the leakage values are small in comparison to the leakage value at which the risk to the public starts to increase over the value of risk corresponding to L_a (approximately $200L_a$, as discussed in NUREG-1493). Therefore, based on these considerations, it is unlikely that an extension of one cycle for the performance of the Appendix J, Type A test at Prairie Island Nuclear Generating Plant, Unit No. 2, would result in significant degradation of the overall containment integrity. As a result, the application of the regulation in these particular circumstances is not necessary to achieve the underlying purpose of the rule. Based on the generic and plant-specific data, the NRC staff finds the basis for the licensee's proposed one-time schedular exemption to allow an extension of one cycle for the performance of the Appendix J, Type A test, provided that the general containment inspection is performed, to be acceptable.

Pursuant to 10 CFR 51.32, the Commission has determined that granting this exemption will not have a significant effect on the quality of the human environment (60 FR 18428).

This exemption is effective upon issuance.

Dated at Rockville, Maryland, this 12th day of April 1995.

For the Nuclear Regulatory Commission.

Elinor G. Adensam,

Acting Director, Division of Reactor Projects III/IV, Office of Nuclear Reactor Regulation.

[FR Doc. 95-9637 Filed 4-18-95; 8:45 am]

BILLING CODE 7590-01-M

Advisory Committee on Medical Uses of Isotopes: Meeting Notice

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of Meeting.

SUMMARY: The U.S. Nuclear Regulatory Commission will convene its next regular meeting of the Advisory Committee on the Medical Uses of Isotopes (ACMUI) on May 11 and 12, 1995. Topics of discussion will include: (1) Brachytherapy issues; (2) Guidance documents for the final Radiopharmacy Rule; (3) Prostate implant procedures; (4) National Program Review II; (5) Training and experience of authorized users to allow exemptions to Subpart J; (6) Dose ranges in written directives; (7) Petition to review the final Radiopharmacy Rule; (8) Information from NIST on Sr-90 calibration errors for eye applicators; (9) Revisions to Regulatory Guide 10.8; (10) Status of implementation of the Quality Management rule; (11) Update on the study of the medical use program by the National Academy of Science; (12) Summary of "Business Process Reengineering;" (13) Update on rulemakings: "Medical Administration of Radiation and Radioactive Materials," "Release of Patients Containing Radiopharmaceuticals or Permanent Implants," and "Administration of Byproduct Material or Radiation from Byproduct Material to Patients who may be Pregnant or Nursing."

DATES: The meeting will begin at 8 a.m. on May 11 and 12, 1995.

ADDRESSES: U.S. Nuclear Regulatory Commission, Two White Flint North, 11545 Rockville Pike, Room T2B3, Rockville, MD 20852-2738.

FOR FURTHER INFORMATION CONTACT: Josephine M. Piccone, Ph.D., U.S. Nuclear Regulatory Commission, Office of Nuclear Material Safety and Safeguards, MS T8F5, Washington, DC 20555, Telephone (301) 415-7270. For

administrative information, contact Torre Taylor, (301) 415-7900.

Conduct of the Meeting

Barry Siegel, M.D., will chair the meeting. Dr. Siegel will conduct the meeting in a manner that will facilitate the orderly conduct of business. The following procedures apply to public participation in the meeting:

1. Persons who wish to provide a written statement should submit a reproducible copy to Josephine M. Piccone (address listed above). Comments must be received by May 3, 1995, to ensure consideration at the meeting. The transcript of the meeting will be kept open until May 19, 1995, for inclusion of written comments.

2. Persons who wish to make oral statements should inform Dr. Piccone in writing, by May 3, 1995. Statements must pertain to the topics on the agenda for the meeting. The Chairman will rule on requests to make oral statements. Members of the public will be permitted to make oral statements if time permits. Permission to make oral statements will be based on the order in which requests are received. In general, oral statements will be limited to approximately 5 minutes. Oral statements must be supplemented by detailed written statements for the record. Rulings on who may speak, the order of presentation, and time allotments may be obtained by calling Dr. Piccone, (301) 415-7270, between 8 a.m. and 4 p.m., EST, on May 9, 1995.

3. At the meeting, questions from attendees other than committee members, NRC consultants, and NRC staff will be permitted at the discretion of the Chairman.

4. The transcript, minutes of the meeting, and written comments will be available for inspection, and copying, for a fee, at the NRC Public Document Room, 2120 L Street NW, Lower Level, Washington, DC 20555 (202) 634-3273, on or about May 26, 1995.

5. Seating for the public will be on a first-come, first-served basis.

This meeting will be held in accordance with the Atomic Energy Act of 1954, as amended (primarily Section 161a); the Federal Advisory Committee Act (5 U.S.C. App); and the Commission's regulations in Title 10, *Code of Federal Regulations*, Part 7.

Dated: April 13, 1995.

Andrew L. Bates,

Advisory Committee Management Officer.

[FR Doc. 95-9638 Filed 4-18-95; 8:45 am]

BILLING CODE 7590-01-M